National Health Surveillance Agency (ANVISA)

National Health Surveillance Agency (ANVISA)
Name	National Health Surveillance Agency (ANVISA)
Native name	Agência Nacional de Vigilância Sanitária
Formed	1999
Jurisdiction	Brazil
Headquarters	Brasília
Chief1 name	Rita de Cássia
Chief1 position	Director-President
Parent department	Ministry of Health
Website	ANVISA

National Health Surveillance Agency (ANVISA) The National Health Surveillance Agency (ANVISA) is the Brazilian federal regulatory authority responsible for oversight of health-related products and services, created to centralize functions formerly dispersed among Ministry of Health (Brazil), National Health Foundation (Brazil), Institute of Drug and Food Control, and other bodies. ANVISA's mandate integrates regulatory activities across pharmaceuticals, medical devices, food safety, cosmetics, and sanitary control in ports and airports, operating within the legal framework established by Constitution of Brazil and regulatory statutes such as Law No. 9.782/1999. It interacts with national institutions including Brazilian Health Regulatory Agency, Supreme Federal Court (Brazil), National Congress of Brazil, and sectoral stakeholders like Brazilian Federation of Hospitals.

History

ANVISA was established in 1999 under President Fernando Henrique Cardoso amid a wave of administrative reforms influenced by models from Food and Drug Administration, European Medicines Agency, and regulatory modernization efforts linked to World Health Organization recommendations. Early history involved consolidation of functions from agencies such as National Institute of Food and Drug Control (historical), coordination with National Immunization Program (Brazil), and responses to public health crises like the 1999 meningitis outbreak and challenges following the 1990s vaccine controversies in Brazil. In the 2000s ANVISA expanded through landmark regulatory actions influenced by cases involving Oswaldo Cruz Foundation, Butantan Institute, and private pharmaceutical companies like Fiocruz partners and multinational firms such as Pfizer and GlaxoSmithKline. Legal and political milestones included adjudication by the Superior Court of Justice (Brazil), budgetary oversight by the Federal Court of Accounts (Brazil), and legislative adjustments from the Ministry of Planning (Brazil). Recent history reflects engagement with crises including the Zika virus epidemic, the 2014 FIFA World Cup in Brazil public health preparations, and the COVID-19 pandemic responses involving institutions like Anatel, ANPPREV, and Brazilian National Research Ethics Commission.

Organization and Governance

ANVISA's leadership structure comprises a collegiate board and a director-president appointed under provisions of Brazilian Administrative Law, with governance interface to the Ministry of Health (Brazil), National Health Council (Brazil), and oversight by the Federal Court of Accounts (Brazil). Internally, technical divisions coordinate regulatory reviews with input from advisory committees drawing experts from Oswaldo Cruz Foundation, Butantan Institute, University of São Paulo, Federal University of Rio de Janeiro, and research bodies such as Fiocruz. ANVISA engages with legal bodies including the Superior Electoral Court (Brazil) for compliance, and aligns budgets with guidelines from the Ministry of Finance (Brazil) and the National Treasury of Brazil. Governance reforms have been influenced by comparisons to European Commission, United States Congress oversight of agencies, and recommendations from World Bank and Inter-American Development Bank evaluations.

Regulatory Functions and Areas of Activity

ANVISA regulates pharmaceuticals, vaccines, medical devices, blood products, food safety, cosmetics, tobacco products, and sanitary surveillance at points of entry, following norms referenced to World Health Organization, Pan American Health Organization, Codex Alimentarius, and regional standards from Mercosur. Its pharmaceutical regulation involves registration, Good Manufacturing Practice audits, and pharmacovigilance linked with stakeholders like Brazilian Association of Pharmaceutical Companies, National Association of Pharmacies, and multinational manufacturers including Novartis, Roche, and Johnson & Johnson. In food safety ANVISA issues sanitary standards interacting with Ministry of Agriculture, Livestock and Food Supply (Brazil), Brazilian Agricultural Research Corporation (Embrapa), and supply chain actors such as BRF S.A. and JBS S.A.. Other activity areas include regulation of tobacco per WHO Framework Convention on Tobacco Control, control of cosmetic approvals, oversight of blood banks coordinated with National Blood Program (Brazil), and sanitary inspections at airports such as Santos Dumont Airport and seaports like Port of Santos.

Licensing, Inspection, and Enforcement

ANVISA issues marketing authorizations, manufacturing licenses, and conducts inspections under Good Manufacturing Practices, coordinating enforcement with state health secretariats such as São Paulo State Department of Health and municipal agencies like São Paulo Municipal Health Department. Inspections and enforcement actions have targeted manufacturers including EMS S.A., distributors, and informal markets linked to cases adjudicated by the Superior Court of Justice (Brazil). Enforcement tools include seizure, fines pursuant to Administrative Procedure Law (Brazil), and product recalls coordinated with Brazilian Consumer Protection Code mechanisms, while judicial appeals have been heard before the Supreme Federal Court (Brazil) and federal courts. Transparency measures include public registries, inspection reports, and collaboration with anti-corruption bodies like Office of the Comptroller General (Brazil).

Public Health Impact and Controversies

ANVISA's interventions have influenced vaccination programs administered by National Immunization Program (Brazil), responses to outbreaks such as Zika virus epidemic and Dengue fever, and drug orphan designation policies interacting with patient advocacy groups including Movement for Access to Medicines (Brazil). Controversies have arisen over accelerated approvals during health emergencies, intellectual property disputes involving Pharmaceutical Research and Manufacturers of America (PhRMA), price regulation tensions with National Supplementary Health Agency (ANS), and conflicts with industry actors like Bayer and Abbott Laboratories. Public debates also involved regulatory transparency, importation of unregistered products, and adjudication of cases in the Federal Supreme Court (Brazil), prompting reforms influenced by civil society organizations such as Brazilian Institute for Consumer Defense.

International Relations and Cooperation

ANVISA maintains cooperation agreements with international regulators including European Medicines Agency, United States Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency (UK), and multilateral bodies like World Health Organization and Pan American Health Organization. It participates in regional initiatives under Mercosur Health Working Group, information-sharing networks with International Coalition of Medicines Regulatory Authorities, and technical cooperation with research partners such as Oswaldo Cruz Foundation and Butantan Institute. Cross-border activities include joint inspections, regulatory harmonization projects with ANMAT (Argentina), and engagement in global responses coordinated through World Health Assembly mechanisms.

Category:Government agencies of Brazil Category:Medical and health organizations Category:Regulatory agencies